| 1 |
Zahedi N, Pourajam S, Zaker E, Kouhpayeh S, Mirbod SM, Tavangar M, Boshtam M, Hatami Kahkesh K, Qian Q, Zhang F, Shariati L, Khanahmad H, Boshtam M. The potential therapeutic impacts of trehalose on cardiovascular diseases as the environmental-influenced disorders: An overview of contemporary findings. Environ Res 2023;226:115674. [PMID: 36925035 DOI: 10.1016/j.envres.2023.115674] [Reference Citation Analysis]
|
| 2 |
Zhang P, Sun Y, Shi L, Sun D, Wang L, Feng D, Ding C. Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of bladder cancer by activating PPARγ/PTEN/AKT pathway. Tissue Cell 2023;82:102048. [PMID: 36905861 DOI: 10.1016/j.tice.2023.102048] [Reference Citation Analysis]
|
| 3 |
Farasati Far B, Naimi-Jamal MR, Daneshgar H, Rabiee N. Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment. Environ Res 2023;225:115589. [PMID: 36858304 DOI: 10.1016/j.envres.2023.115589] [Reference Citation Analysis]
|
| 4 |
Nosrati H, Salehiabar M, Charmi J, Yaray K, Ghaffarlou M, Balcioglu E, Ertas YN. Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles. ACS Appl Bio Mater 2023;6:784-92. [PMID: 36693820 DOI: 10.1021/acsabm.2c00965] [Reference Citation Analysis]
|
| 5 |
Jin M, Zhao Y, Guan ZJ, Fang Y. Porous Framework Materials for Bioimaging and Cancer Therapy. Molecules 2023;28. [PMID: 36771027 DOI: 10.3390/molecules28031360] [Reference Citation Analysis]
|
| 6 |
Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MASB, Salimimoghadam S, Aref AR, Kalbasi A, Rajabi R, Rashidi M, Taheriazam A, Sethi G. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacol Res 2023;187:106553. [PMID: 36400343 DOI: 10.1016/j.phrs.2022.106553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, Rezaei S, Hejazi ES, Kakavand A, Heidari H, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. SOX2 function in cancers: Association with growth, invasion, stemness and therapy response. Biomedicine & Pharmacotherapy 2022;156:113860. [DOI: 10.1016/j.biopha.2022.113860] [Reference Citation Analysis]
|
| 8 |
Hashemi M, Ghadyani F, Hasani S, Olyaee Y, Raei B, Khodadadi M, Ziyarani MF, Basti FA, Tavakolpournegari A, Matinahmadi A, Salimimoghadam S, Aref AR, Taheriazam A, Entezari M, Ertas YN. Nanoliposomes for doxorubicin delivery: Reversing drug resistance, stimuli-responsive carriers and clinical translation. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.104112] [Reference Citation Analysis]
|
| 9 |
Hashemi M, Mirzaei S, Barati M, Hejazi ES, Kakavand A, Entezari M, Salimimoghadam S, Kalbasi A, Rashidi M, Taheriazam A, Sethi G. Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. Life Sci 2022;309:120984. [PMID: 36150461 DOI: 10.1016/j.lfs.2022.120984] [Reference Citation Analysis]
|
| 10 |
Sadrkhanloo M, Entezari M, Rashidi M, Hashemi M, Raesi R, Saghari S, Daneshi S, Salimimoghadam S, Hushmandi K, Mirzaei S, Taheriazam A. Non-coding RNAs in EMT regulation: Association with tumor progression and therapy response. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
